This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ultragenyx (RARE) Surges on Product Approvals, Pipeline Progress
by Zacks Equity Research
Ultragenyx (RARE), which has a strong pipeline, receives a few approvals for its products in 2020.
New Strong Sell Stocks for December 9th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Sarepta (SRPT) DMD Study Shows Proof of Concept for SRP-5051
by Zacks Equity Research
Sarepta's (SRPT) ongoing phase II study data supports continued dose escalation of SRP-5051 and suggests improved efficacy on lower doses compared to Exondys 51.
Are Options Traders Betting on a Big Move in Solid Biosciences (SLDB) Stock?
by Zacks Equity Research
Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.
Solid Biosciences (SLDB) Reports Wider-Than Expected Q3 Loss
by Zacks Equity Research
Solid Biosciences??? (SLDB) reports wider than expected loss in the third quarter of 2020.
Solid Biosciences (SLDB) to PostQ3 Earnings: What's in Store?
by Zacks Equity Research
Solid Biosciences (SLDB) will provide updates on its lead pipeline candidate,SGT-001, along with others when it releases third-quarter 2020 results.
Do Options Traders Know Something About Solid Biosciences (SLDB) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.
Sarepta's Casimersen NDA Gets Priority Review From FDA
by Zacks Equity Research
Sarepta (SRPT) is seeking accelerated approval for exon 45 amenable DMD candidate, casimersen. Amondys 45 is likely to be the brand name for the candidate.
Sarepta Completes Rolling NDA Submission for New DMD Therapy
by Zacks Equity Research
Sarepta (SRPT) is seeking accelerated approval for its third exon-skipping therapy, casimersen, for DMD patients.
Sarepta Inks Agreement With Codiak to Develop Gene Therapies
by Zacks Equity Research
Sarepta (SRPT) and Codiak BioSciences sign agreement to develop potential gene therapies targeting neuromuscular indications using Codiak's engineered exosomes.
Sarepta's Gene Therapy Promising in Muscular Dystrophy Study
by Zacks Equity Research
Sarepta's (SRPT) gene therapy candidate for treating limb-girdle muscular dystrophy shows continued functional improvement over a year for the lower dose as well as increasing efficacy with higher dose.
Why Solid Biosciences (SLDB) Stock Might be a Great Pick
by Zacks Equity Research
Solid Biosciences (SLDB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy
by Zacks Equity Research
Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.
Top Ranked Momentum Stocks to Buy for May 13th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 13th.
Applied Genetic Stock Up on Favorable Eye Therapy Study Data
by Zacks Equity Research
Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.
Sarepta Signs Gene Therapy Agreement With Roche for $1.15B
by Zacks Equity Research
Sarepta (SRPT) grants ex-U.S. marketing rights of its gene therapy DMD candidate, SRP-9001, to Roche for an upfront payment of $1.15 billion. Sarepta is also eligible to receive $1.7 billion in milestone payments.
Options Traders Expect Huge Moves in Solid Biosciences (SLDB) Stock
by Zacks Equity Research
Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.
Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up
by Zacks Equity Research
Sarepta (SRPT) exon-53 skipping DMD drug, Vyondys 53, gets approval in the United States following a CRL in August.
Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
Will Solid Biosciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Solid Biosciences.
Sarepta Stock Falls as FDA Denies Approval to Golodirsen
by Zacks Equity Research
The CRL to golodirsen NDA comes as a surprise for Sarepta (SRPT) and investors as no issues were raised by the FDA during the review period that could have lead to non-approval of the candidate.
Solid Biosciences Surges on DMD Gene Therapy Study Amendments
by Zacks Equity Research
Solid Biosciences (SLDB) amends its phase I/II gene therapy study protocol to expedite the development of its lead candidate, SGT-001, as potential treatment for DMD.
Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval
by Zacks Equity Research
Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year. The company plans expansion of gene therapy program into other indications including multiple sclerosis.
Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues
by Zacks Equity Research
Sarepta's (SRPT) shares surge after safety issues are observed in Pfizer's early-stage clinical study related to its gene therapy for DMD.
Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study
by Zacks Equity Research
Pfizer (PFE) presents early data from a study on its investigational gene therapy for DMD. However, the study highlighted some serious side effects in two out of the six participants.